Stocks Health care PHIO
NASDAQ · Health carePhio Pharmaceuticals Corp. (PHIO)
It posted a net loss of $12.9M. In fiscal 2025 capital spending exceeded operating cash flow by $8M. At June 30, 2026 it held $13M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Phio Pharmaceuticals Corp.
- Net worth
- Phio Pharmaceuticals Corp. has a market value (market cap) of $9.5M at the latest share price, and shareholders' equity of $12.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $0 (-100.0% year on year), with a net loss of $8.8M.
- Cash flow
- In fiscal 2025 operations used $8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Phio Pharmaceuticals Corp.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Phio Pharmaceuticals Corp. does
Phio Pharmaceuticals Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8.7M | -$1.45 | -$8M |
| 2024 | n/a | -$7.2M | -$9.08 | -$7.1M |
| 2023 | n/a | -$10.8M | -$46.76 | -$10.8M |
| 2022 | n/a | -$11.5M | -$90.82 | -$12.3M |
| 2021 | n/a | -$13.3M | -$111.77 | -$11.9M |
| 2020 | $0 | -$8.8M | -$206.35 | -$8.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Phio Pharmaceuticals Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026
- September 28, 2026Executive or director change8-KPhio Pharmaceuticals stockholders approved an equity incentive plan amendment and elected six directors at the 2026 Annual Meeting.
- September 14, 2026Other event 8-K
- August 14, 2026
- August 14, 2026Additional proxy material DEFA14A
- August 14, 2026Proxy statement DEF 14A
- August 6, 2026
- August 6, 2026
- July 21, 2026
- May 7, 2026
Insider trades
What the people running Phio Pharmaceuticals Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $59.1K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Plott Ronald ToddDirector | Bought | 5,000 | $5.2K |
| September 28, 2026 | Plott Ronald ToddDirector | Bought | 5,000 | $5.2K |
| September 28, 2026 | Carson Lisa CabottChief Financial Officer | Received as pay | 108,000 | - |
| September 28, 2026 | Plott Ronald ToddDirector | Received as pay | 17,000 | - |
| September 28, 2026 | Bitterman Robert JChairman, Pres. & CEO, Director | Received as pay | 400,000 | - |
| September 24, 2026 | Bradford Patricia ADirector | Bought | 6,500 | $6.6K |
| September 22, 2026 | Bitterman Robert JChairman, Pres. & CEO, Director | Bought | 2,000 | $2.1K |
| September 15, 2026 | Bradford Patricia ADirector | Bought | 12,000 | $12.4K |
Who owns PHIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | February 17, 2026 |
| Mitchell P. Kopin13G, passive with 2 related filers | 9.1% | February 13, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 1,165,744 shares in total, about $948.7K at the last price.
| Holder | Shares |
|---|---|
| Bitterman Robert JChairman, Pres. & CEO, Director | 764,871 |
| Carson Lisa CabottChief Financial Officer | 189,112 |
| Bradford Patricia ADirector | 64,151 |
| Plott Ronald ToddDirector | 42,000 |
| Deming David HDirector | 37,800 |
| Lockshin CurtisDirector | 35,155 |
| Freeman Jonathan EDirector | 32,655 |
Questions about PHIO
What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp. is a company in the Health care sector, listed on NASDAQ as PHIO. Its shares trade on NASDAQ under the ticker PHIO.
What is Phio Pharmaceuticals Corp.'s net worth?
Phio Pharmaceuticals Corp. has a market value (market cap) of $9.5M at the latest share price, and shareholders' equity of $12.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Phio Pharmaceuticals Corp. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.9M.
When did Phio Pharmaceuticals Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 30, 2026.
When is Phio Pharmaceuticals Corp.'s next earnings report?
Phio Pharmaceuticals Corp.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PHIO with
Follow PHIO
Get an email when Phio Pharmaceuticals Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Phio Pharmaceuticals Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.